BACKGROUND: The anti-aquaporin4 (anti-AQP4) antibody is specific for neuromyelitis optica (NMO), but is also found in limited forms. The presence of this antibody in acute transverse myelitis (ATM) has been associated with recurrence and conversion to NMO, but the influence on disability has not yet been described. OBJECTIVE: To describe the frequency of anti-AQP4 in ATM and analyze the influence in long-term prognosis. DESIGN: Cross-sectional and retrospective study. METHODS: Consecutive ATM cases in a multiple sclerosis center in Rio de Janeiro, Brazil, from 2000 through 2009 were reviewed. Recurrent cases tested for anti-AQP4 were selected. ATM with magnetic resonance imaging spinal cord lesions extending over three or more vertebral segments was classified as longitudinally extensive transverse myelitis (LETM); Kurtzke scale was applied at last evaluation. OUTCOME MEASURES: Frequency of anti-AQP4; severity of spinal cord dysfunction at last follow-up. RESULTS: Twenty six patients (21 female:5 male; 17 white:9 African descent) were studied. The first ATM occurred at 38.04 ± 12.7 years. The interval between the first and the second ATM was eight months (1-150) and the number of ATM varied from two to seven. After 40.5 months (12-192) of disease, the median Expanded Disability Status Scale (EDSS) score was three (0-9). Anti-AQP4 antibody was positive in 26.9%. LETM was found in 65.4%. LETM presented later onset, higher disability and higher positivity to anti-AQP4 (LETM 41.2% versus no-LETM 0%, P = 0.024). Dysfunction at long-term follow-up was similar in anti-AQP4 positive and negative cases. CONCLUSION: The frequency of anti-AQP4 in recurrent ATM was 26.9%, increasing to 41.2% among LETM. Presence of the antibody had no influence on morbidity.
BACKGROUND: The anti-aquaporin4 (anti-AQP4) antibody is specific for neuromyelitis optica (NMO), but is also found in limited forms. The presence of this antibody in acute transverse myelitis (ATM) has been associated with recurrence and conversion to NMO, but the influence on disability has not yet been described. OBJECTIVE: To describe the frequency of anti-AQP4 in ATM and analyze the influence in long-term prognosis. DESIGN: Cross-sectional and retrospective study. METHODS: Consecutive ATM cases in a multiple sclerosis center in Rio de Janeiro, Brazil, from 2000 through 2009 were reviewed. Recurrent cases tested for anti-AQP4 were selected. ATM with magnetic resonance imaging spinal cord lesions extending over three or more vertebral segments was classified as longitudinally extensive transverse myelitis (LETM); Kurtzke scale was applied at last evaluation. OUTCOME MEASURES: Frequency of anti-AQP4; severity of spinal cord dysfunction at last follow-up. RESULTS: Twenty six patients (21 female:5 male; 17 white:9 African descent) were studied. The first ATM occurred at 38.04 ± 12.7 years. The interval between the first and the second ATM was eight months (1-150) and the number of ATM varied from two to seven. After 40.5 months (12-192) of disease, the median Expanded Disability Status Scale (EDSS) score was three (0-9). Anti-AQP4 antibody was positive in 26.9%. LETM was found in 65.4%. LETM presented later onset, higher disability and higher positivity to anti-AQP4 (LETM 41.2% versus no-LETM 0%, P = 0.024). Dysfunction at long-term follow-up was similar in anti-AQP4 positive and negative cases. CONCLUSION: The frequency of anti-AQP4 in recurrent ATM was 26.9%, increasing to 41.2% among LETM. Presence of the antibody had no influence on morbidity.
Authors: I Nakashima; K Fujihara; I Miyazawa; T Misu; K Narikawa; M Nakamura; S Watanabe; T Takahashi; S Nishiyama; Y Shiga; S Sato; B G Weinshenker; Y Itoyama Journal: J Neurol Neurosurg Psychiatry Date: 2006-02-27 Impact factor: 10.154
Authors: Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker Journal: Lancet Date: 2004 Dec 11-17 Impact factor: 79.321
Authors: Patrick Waters; Sven Jarius; Edward Littleton; Maria Isabel Leite; Saiju Jacob; Bryony Gray; Ruth Geraldes; Thomas Vale; Anu Jacob; Jacqueline Palace; Susan Maxwell; David Beeson; Angela Vincent Journal: Arch Neurol Date: 2008-07
Authors: Regina Maria Papais-Alvarenga; Claudia Cristina Ferreira Vasconcelos; Adriana Carra; Ibis Soto de Castillo; Sara Florentin; Fernando Hamuy Diaz de Bedoya; Raul Mandler; Luiza Campanella de Siervi; Maria Lúcia Vellutini Pimentel; Marina Papais Alvarenga; Marcos Papais Alvarenga; Anderson Kuntz Grzesiuk; Ana Beatriz Calmon Gama Pereira; Antonio Pereira Gomes Neto; Carolina Velasquez; Carlos Soublette; Cynthia Veronica Fleitas; Denise Sisteroli Diniz; Elizabeth Armas; Elizabeth Batista; Freda Hernandez; Fernanda Ferreira Chaves da Costa Pereira; Heloise Helena Siqueira; Hideraldo Cabeça; Jose Sanchez; Joseph Bruno Bidin Brooks; Marcus Vinicius Gonçalves; Maria Cristina Del Negro Barroso; Maria Elena Ravelo; Maria Carlota Castillo; Maria Lúcia Brito Ferreira; Maria Sheila Guimarães Rocha; Monica Koncke Fiuza Parolin; Omaira Molina; Patricia Beatriz Christino Marinho; Paulo Pereira Christo; Renata Brant de Souza; Silvio Pessanha Neto; Solange Maria das Graças Camargo; Suzana Costa Machado; Vanderson Carvalho Neri; Yara Dadalti Fragoso; Helcio Alvarenga; Luiz Claudio Santos Thuler Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240